Annual Report - Glenmark

More documents

Recommendations

Info

Integrated 8 Glenmark's business strategy is balanced by a comprehensive risk management approach that extends from the top of the pyramid [business blueprint] to the bottom [individual product baskets]. The model comprises a keen research focus, diverse geographic presence, wider product basket, superior manufacturing facilities, quicker regulatory approvals and an ongoing investment in human competencies. The Company's integrated business model, itself, exemplifies its fundamental risk management initiative, which has translated into a lower cost structure and a direct control over an increasing number of links in the value chain. Additionally, this approach also creates a revenue source from each of these links, viz. potential licensing opportunities for new drugs, a growing presence as a bulk supplier and formulations player in various markets. of the international markets. Gradual reduction in the dependence on the Indian formulations business [from almost 100 percent of turnover in 2000 to 50 percent in 2005]. Concentration on strengthening the Company's product basket with new value-added therapies and product introductions across more territories globally. Acceleration of product launches and DMF/ANDA filings through enhanced quality systems and a strong regulatory focus to drive revenues. Profiting from local know-how by recruitment of local management in several of its key markets. It is this combination of sound risk management and rapid revenue and profit growth that will help the Company improve value for its shareholders. This integrated method of business has also been enhanced by the following means: Creation of world-class manufacturing facilities to address quality demands and strict regulations
Success in a competitive global environment is achieved by anticipating the perils and meeting them with a risk-mitigation strategy. Annual Report 2004-2005 9
Page 1 and 2: Glenmark Pharmaceuticals Limited An
Page 3: Consolidated Financial Highlights Y
Page 6 and 7: Global. Research-focused. Integrate
Page 8 and 9: Global accounts for half the global
Page 10 and 11: Research-focused 6 In the post-GATT
Page 14 and 15: Highlights, 2004-05 Consolidated re
Page 16 and 17: Interview with MD & CEO 12 Glenn Sa
Page 18 and 19: Our lead compound for Asthma and CO
Page 20 and 21: Business Divisional Analysis 16 Ind
Page 22 and 23: Domestic Formulations Performance H
Page 24 and 25: 20 accounted for almost 50 percent
Page 26 and 27: Active Pharmaceutical Ingredients 2
Page 28 and 29: Therapeutic segment contribution in
Page 30 and 31: International Formulations Performa
Page 32 and 33: 28 percent evinced a growth spurt i
Page 34 and 35: Research and Development 30 JANUARY
Page 36 and 37: 32 compounds are licensed to global
Page 38 and 39: Diabetes/Obesity Incidence Globally
Page 40 and 41: Global Management Team Name Glenn S
Page 42 and 43: 38 Revenues Glenmark's turnover for
Page 44 and 45: 40 Secured Loans Secured loans incr
Page 46 and 47: existing employees to keep them in
Page 48 and 49: 44 who are geared to respond to and
Page 50 and 51: Profit & loss Account (Rs. in ‘00
Page 52 and 53: PAT Margin Research and development
Page 54 and 55: Directors’ Report Your Directors
Page 56 and 57: 52 of the Company. On exercising th
Page 58 and 59: Annexure to the Directors’ Report
Page 60 and 61: v. The products launched and sold i
Page 62 and 63:
Disclosure pursuant to the provisio
Page 64 and 65:
Report on Corporate Governance Purs
Page 66 and 67:
B. Given below are the details of r
Page 68 and 69:
He is also a Director of following
Page 70 and 71:
Further resolutions with requisite
Page 72 and 73:
(All figures in Indian Rupees) Mont
Page 74 and 75:
) Risk as to fraudulent encashment
Page 76 and 77:
ANNEXURE TO AUDITORS’ REPORT Refe
Page 78 and 79:
Balance Sheet Rs. In (’000s) As a
Page 80 and 81:
Cash Flow Statement Rs. In (’000s
Page 82 and 83:
Schedules forming part of the Balan
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Schedules to the Profit & Loss Acco
Page 92 and 93:
Schedules forming part of the Finan
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
100 SECTION 212 STATEMENT PURSUANT
Page 106 and 107:
Consolidated Balance Sheet Rs. In (
Page 108 and 109:
Consolidated Cash Flow Statement Rs
Page 110 and 111:
Schedules forming part of the Conso
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
114 Notes to the Consolidated Accou
Page 120 and 121:
Notes to the Consolidated Accounts
Page 122 and 123:
118 Notes to the Consolidated Accou
Page 124:
14 13 12 43 19 71 49 10 5 20 62 3 3
show all

Annual Report - Glenmark

Create successful ePaper yourself

Delete template?

Save as template?